Wiley (NYSE: WLY) and OpenEvidence announced a strategic partnership that will embed Wiley’s extensive scientific and medical content—including the Cochrane Database of Systematic Reviews and Cochrane Clinical Answers—directly into OpenEvidence’s point‑of‑care AI platform, giving clinicians instant access to vetted research at the bedside.
Wiley’s recent financial performance shows a modest revenue increase of 1% in Q3 2025, while adjusted earnings per share rose 39%. In the most recent quarter, Q2 2026, Wiley reported an EPS of $1.10, beating forecasts, but revenue fell short of expectations, indicating a mix of strong core‑segment demand and headwinds in legacy product lines.
OpenEvidence, which raised a $250 million Series D round in January 2026, has surpassed $100 million in annual revenue and is valued at $12 billion. The partnership positions OpenEvidence to monetize its platform further by leveraging Wiley’s authoritative content library.
The integration will prioritize high‑impact content such as peer‑reviewed journals, books, and databases, with a focus on clinical decision support tools that can be accessed within the OpenEvidence interface. This scope aligns with the company’s goal of delivering evidence‑based recommendations in real time.
Strategically, the deal taps into the rapidly expanding AI‑in‑healthcare market, projected to reach hundreds of billions of dollars by 2030. For Wiley, it advances its broader AI strategy of embedding content into digital tools, while for OpenEvidence it strengthens its value proposition by offering clinicians trusted research, potentially increasing user adoption and retention.
The partnership is expected to improve physicians’ ability to make evidence‑based decisions, reduce information overload, and enhance patient outcomes. By combining Wiley’s editorial rigor with OpenEvidence’s AI delivery, the collaboration could set a new standard for point‑of‑care decision support.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.